Skip to Content

Press Releases

Press Releases

May 07 2019
Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update
JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three months ended March 31, 2019 and provides a corporate update.  Highlights of the first quarter 2019 and recent weeks include: Announced that the last
May 02 2019
Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders
JERUSALEM , May 2, 2019 /PRNewswire/  -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) was accepted for presentation in
Apr 30 2019
Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients
Company on track to report top-line data in July/August time frame JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the last patient has completed their final visit in the Company's pivotal Phase 3 trial (the ACCORDANCE
Apr 01 2019
Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference
JERUSALEM , April 1, 2019 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference . HC Wainwright Global Life Sciences Conference Date: April 7-9, 2019
Mar 13 2019
Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference
Presenting at 8:00 am Eastern time on March 14, 2019 JERUSALEM , March 13, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.
Feb 28 2019
Intec Pharma to Participate at Four Investment Conferences in March
JERUSALEM , Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 39th Annual Health Care Conference Date: March 11-13, 2019 Company
Feb 27 2019
Intec Pharma Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Update
JERUSALEM , Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2018 and provides a corporate update.  Highlights of the fourth quarter 2018 and recent weeks include:
Feb 19 2019
Intec Pharma Reports Positive Results from Pharmacokinetic Study of Accordion Pill™ Carbidopa/Levodopa 50/500 mg Dosed Three Times Daily
AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance JERUSALEM , Feb. 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the preliminary results from a pharmacokinetic
Jan 02 2019
Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC
Pursuing medical cannabinoids for a variety of pain indications JERUSALEM , Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion
Dec 19 2018
Intec Pharma Publishes Letter to Shareholders
Reviews 2018 progress and provides outlook for 2019 JERUSALEM , Dec. 19, 2018 /PRNewswire/ --    Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Jeffrey A. Meckler , Vice Chairman and Chief Executive Officer of Intec Pharma , has issued a Letter to Shareholders,
Displaying 11 - 20 of 95